<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03911921</url>
  </required_header>
  <id_info>
    <org_study_id>FATIGUE</org_study_id>
    <secondary_id>PZ2017019</secondary_id>
    <nct_id>NCT03911921</nct_id>
  </id_info>
  <brief_title>RSYR for Fatigue Reduction in Cancer Survivors</brief_title>
  <official_title>Renshen Yangrong Tang (RSYRT) for Reducing Fatigue in Cancer Survivors: A Phase II Randomized Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Beijing Cancer Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Beijing Cancer Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This randomized Phase II trial to establish the efficacy of traditional Chinese medicine
      (TCM) herbal products above control group for treating fatigue in patients with cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients who were randomized and been enrolled in, had stable disease and no anemia, and
      reported moderate to severe fatigue over two months (rated â‰¥4 on a 0-10 scale). Patients took
      TCM decoction Renshen Yangrong decoction (RSYR),Which containing 12 TCM herbs, twice a day
      for 6 weeks. RSYRT aims to correct Qi deficiency. Fatigue was assessed before and after RSYRT
      therapy.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 1, 2015</start_date>
  <completion_date type="Actual">February 1, 2019</completion_date>
  <primary_completion_date type="Actual">February 1, 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>a randomized Phase II trial</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Fatigue score</measure>
    <time_frame>6 weeks</time_frame>
    <description>Self-assessed 24-hour fatigue symptom score. According to the NCCN fatigue guide, the score is 0-10 points, 0 points means no fatigue, 10 points means the most serious fatigue that can be imagined.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">92</enrollment>
  <condition>Cancer-related Problem/Condition</condition>
  <arm_group>
    <arm_group_label>RSYYT decoction</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>RSYYT decoction Compound granules of traditional Chinese medicine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Astragalus membranaceus</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>one herb decoction Compound granules of one herb (Astragalus membranaceus)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>RSYRT decoction</intervention_name>
    <description>Compound granules of traditional Chinese medicine</description>
    <arm_group_label>RSYYT decoction</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Astragalus membranaceus</intervention_name>
    <description>One herb</description>
    <arm_group_label>Astragalus membranaceus</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Pathological diagnosis of malignant tumors; 3 months without surgery, radiotherapy and
        chemotherapy, biological treatment; Hemoglobin &gt; 11g/L; Complete remission of the lesion,
        or recent review of the Disease is stable, the estimated survival time is more than 6
        months; ECOG score is 0-2, fatigue score of the last 24 hours &gt; 4 ; Age is 18-65 years old;
        TCM syndrome differentiation for deficiency of qi; Liver, kidney function, electrolyte
        normal; Willing to join the group and sign the informed consent.

        Exclusion Criteria:

        Allergies to herbs and plant drugs; Uncontrollable diabetes, hypertension, TSH
        abnormalities, uncontrollable pain, and a history of myocardial infarction within 6 months;
        Scores of anxiety disorders and depression (HAD-D) were 11 or more, antidepressants and
        antioxidants were used in the past month; Breast cancer receptor positive patients took
        endocrine therapy drugs; Tonics were used in the past 2 weeks.; Children, pregnant and
        lactating women; Receiving anemia-related treatment; Chinese medicine syndrome
        differentiation with excessive heat; Unable to read or understand the scale.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pingping Li, Prof.</last_name>
    <role>Study Director</role>
    <affiliation>Beijing Cancer Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ting Lu, Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Beijing Cancer Hospital</affiliation>
  </overall_official>
  <verification_date>April 2019</verification_date>
  <study_first_submitted>April 10, 2019</study_first_submitted>
  <study_first_submitted_qc>April 10, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">April 11, 2019</study_first_posted>
  <last_update_submitted>April 12, 2019</last_update_submitted>
  <last_update_submitted_qc>April 12, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">April 16, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Beijing Cancer Hospital</investigator_affiliation>
    <investigator_full_name>Yichen Xu</investigator_full_name>
    <investigator_title>Research leader</investigator_title>
  </responsible_party>
  <keyword>Fatigue, Cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fatigue</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

